Coactivation of TLR4 and TLR2/6 coordinates an additive augmentation on IL-6 gene transcription via p38MAPK pathway in U937 mononuclear cells

Molecular Immunology

Volumn 49, Issue 3, 2011, Pages 423-432

  Jin, Junfei ^b   Samuvel, Devadoss J ^b   Zhang, Xiaoming ^b   Li, Yanchun ^b   Lu, Zhongyang ^b   Lopes Virella, Maria F ^a,b   Huang, Yan ^a,b  

^a RALPH H JOHNSON VA MEDICAL CENTER   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Inflammation; Interleukin 6; P38 mitogen activated protein kinase; Toll like receptor

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 6;

ARTICLE; CELL STRAIN U937; CONTROLLED STUDY; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

CELL LINE, TUMOR; HUMANS; INTERLEUKIN-6; MAP KINASE SIGNALING SYSTEM; NF-KAPPA B; RNA STABILITY; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 4; TOLL-LIKE RECEPTOR 6; TRANSCRIPTION, GENETIC;

EID: 81955167451     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2011.08.026     Document Type: Article

References (52)

1. Akira S., Kishimoto T. IL-6 and NF-IL6 in acute-phase response and viral infection. Immunol. Rev. 1992, 127:25-50.
2. Bendtzen K., Buschard K., Diamant M., Horn T., Svenson M. Possible role of IL-1, TNF-alpha, and IL-6 in insulin-dependent diabetes mellitus and autoimmune thyroid disease. Thyroid Cell Group. Lymphokine Res. 1989, 8:335-340.
3. Bjorkbacka H., Kunjathoor V.V., Moore K.J., Koehn S., Ordija C.M., Lee M.A., Means T., Halmen K., Luster A.D., Golenbock D.T., Freeman M.W. Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. Nat. Med. 2004, 10:416-421.
4. Caricilli A.M., Nascimento P.H., Pauli J.R., Tsukumo D.M., Velloso L.A., Carvalheira J.B., Saad M.J. Inhibition of toll-like receptor 2 expression improves insulin sensitivity and signaling in muscle and white adipose tissue of mice fed a high-fat diet. J. Endocrinol. 2008, 199:399-406.
5. Chae H.J., Byun J.O., Chae S.W., Kim H.M., Choi H.I., Pae H.O., Chung H.T., Kim H.R. p38 MAPK and NF-kappaB on IL-6 release in human gingival fibroblasts. Immunopharmacol. Immunotoxicol. 2005, 27:631-646.
6. Dasu M.R., Devaraj S., Park S., Jialal I. Increased toll-like receptor activation and TLR ligands in recently diagnosed type 2 diabetes subjects. Diabetes Care 2010, 33:861-868.
7. Dasu M.R., Devaraj S., Zhao L., Hwang D.H., Jialal I. High glucose induces toll-like receptor expression in human monocytes: mechanism of activation. Diabetes 2008, 57:3090-3098.
8. den Dekker W.K., Cheng C., Pasterkamp G., Duckers H.J. Toll like receptor 4 in atherosclerosis and plaque destabilization. Atherosclerosis 2010, 209:314-320.
9. Devaraj S., Dasu M.R., Park S.H., Jialal I. Increased levels of ligands of Toll-like receptors 2 and 4 in type 1 diabetes. Diabetologia 2009, 52:1665-1668.
10. Devaraj S., Dasu M.R., Rockwood J., Winter W., Griffen S.C., Jialal I. Increased toll-like receptor (TLR) 2 and TLR4 expression in monocytes from patients with type 1 diabetes: further evidence of a proinflammatory state. J. Clin. Endocrinol. Metab. 2008, 93:578-583.
11. Geivelis M., Turner D.W., Pederson E.D., Lamberts B.L. Measurements of interleukin-6 in gingival crevicular fluid from adults with destructive periodontal disease. J. Periodontol. 1993, 64:980-983.
12. Hayes M.M., Lane B.R., King S.R., Markovitz D.M., Coffey M.J. Peroxisome proliferator-activated receptor gamma agonists inhibit HIV-1 replication in macrophages by transcriptional and post-transcriptional effects. J. Biol. Chem. 2002, 277:16913-16919.
13. Hernesniemi J., Lehtimaki T., Rontu R., Islam M.S., Eklund C., Mikkelsson J., Ilveskoski E., Kajander O., Goebeler S., Viiri L.E., Hurme M., Karhunen P.J. Toll-like receptor 4 polymorphism is associated with coronary stenosis but not with the occurrence of acute or old myocardial infarctions. Scand. J. Clin. Lab. Invest. 2006, 66:667-675.
14. Hernesniemi J.A., Raitakari O.T., Kahonen M., Juonala M., Hutri-Kahonen N., Marniemi J., Viikari J., Lehtimaki T. Toll-like receptor 4 gene (Asp299Gly) polymorphism associates with carotid artery elasticity. The cardiovascular risk in young Finns study. Atherosclerosis 2008, 198:152-159.
15. Hirata N., Yanagawa Y., Ebihara T., Seya T., Uematsu S., Akira S., Hayashi F., Iwabuchi K., Onoe K. Selective synergy in anti-inflammatory cytokine production upon cooperated signaling via TLR4 and TLR2 in murine conventional dendritic cells. Mol. Immunol. 2008, 45:2734-2742.
16. Huang Q., Pope R.M. Toll-like receptor signaling: a potential link among rheumatoid arthritis, systemic lupus, and atherosclerosis. J. Leukoc. Biol. 2010, 88:253-262.
17. Ishihara K., Hirano T. IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev. 2002, 13:357-368.
18. Kanczkowski W., Morawietz H., Ziegler C.G., Funk R.H., Schmitz G., Zacharowski K., Mohn C.E., Ehrhart-Bornstein M., Bornstein S.R. Pam3CSK4 and LTA-TLRs ligands associated with microdomains induce IL8 production in human adrenocortical cancer cells. Horm. Metab. Res. 2007, 39:457-460.
19. King G.L. The role of inflammatory cytokines in diabetes and its complications. J. Periodontol. 2008, 79:1527-1534.
20. Kishimoto T. Interleukin-6: discovery of a pleiotropic cytokine. Arthritis Res. Ther. 2006, 8(Suppl. 2):S2.
21. Kristiansen O.P., Mandrup-Poulsen T. Interleukin-6 and diabetes: the good, the bad, or the indifferent?. Diabetes 2005, 54(Suppl. 2):S114-S124.
22. Ley T.J., Connolly N.L., Katamine S., Cheah M.S., Senior R.M., Robbins K.C. Tissue-specific expression and developmental regulation of the human fgr proto-oncogene. Mol. Cell. Biol. 1989, 9:92-99.
23. Li H., Sun B. Toll-like receptor 4 in atherosclerosis. J. Cell. Mol. Med. 2007, 11:88-95.
24. Li Y., Samuvel D.J., Sundararaj K.P., Lopes-Virella M.F., Huang Y. IL-6 and high glucose synergistically upregulate MMP-1 expression by U937 mononuclear phagocytes via ERK1/2 and JNK pathways and c-Jun. J. Cell. Biochem. 2010, 110:248-259.
25. Lin Y.C., Chang Y.M., Yu J.M., Yen J.H., Chang J.G., Hu C.J. Toll-like receptor 4 gene C119A but not Asp299Gly polymorphism is associated with ischemic stroke among ethnic Chinese in Taiwan. Atherosclerosis 2005, 180:305-309.
26. Liu X., Ukai T., Yumoto H., Davey M., Goswami S., Gibson F.C., Genco C.A. Toll-like receptor 2 plays a critical role in the progression of atherosclerosis that is independent of dietary lipids. Atherosclerosis 2008, 196:146-154.
27. Lowe G.D. The relationship between infection, inflammation, and cardiovascular disease: an overview. Ann. Periodontol. 2001, 6:1-8.
28. Michelsen K.S., Wong M.H., Shah P.K., Zhang W., Yano J., Doherty T.M., Akira S., Rajavashisth T.B., Arditi M. Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:10679-10684.
29. Moutsopoulos N.M., Madianos P.N. Low-grade inflammation in chronic infectious diseases: paradigm of periodontal infections. Ann. N. Y. Acad. Sci. 2006, 1088:251-264.
30. Mullick A.E., Tobias P.S., Curtiss L.K. Modulation of atherosclerosis in mice by Toll-like receptor 2. J. Clin. Invest. 2005, 115:3149-3156.
31. Nagpal K., Plantinga T.S., Wong J., Monks B.G., Gay N.J., Netea M.G., Fitzgerald K.A., Golenbock D.T. A TIR domain variant of MyD88 adapter-like (Mal)/TIRAP results in loss of MyD88 binding and reduced TLR2/TLR4 signaling. J. Biol. Chem. 2009, 284:25742-25748.
32. Norata G.D., Garlaschelli K., Ongari M., Raselli S., Grigore L., Benvenuto F., Maggi F.M., Catapano A.L. Effect of the Toll-like receptor 4 (TLR-4) variants on intima-media thickness and monocyte-derived macrophage response to LPS. J. Intern. Med. 2005, 258:21-27.
33. Pankewycz O.G., Guan J.X., Benedict J.F. Cytokines as mediators of autoimmune diabetes and diabetic complications. Endocr. Rev. 1995, 16:164-176.
34. Patil C., Zhu X., Rossa C., Kim Y.J., Kirkwood K.L. p38 MAPK regulates IL-1beta induced IL-6 expression through mRNA stability in osteoblasts. Immunol. Invest. 2004, 33:213-233.
35. Plaisance S., Vanden Berghe W., Boone E., Fiers W., Haegeman G. Recombination signal sequence binding protein Jkappa is constitutively bound to the NF-kappaB site of the interleukin-6 promoter and acts as a negative regulatory factor. Mol. Cell. Biol. 1997, 17:3733-3743.
36. Radin M.S., Sinha S., Bhatt B.A., Dedousis N., O'Doherty R.M. Inhibition or deletion of the lipopolysaccharide receptor Toll-like receptor-4 confers partial protection against lipid-induced insulin resistance in rodent skeletal muscle. Diabetologia 2008, 51:336-346.
37. Rattazzi M., Puato M., Faggin E., Bertipaglia B., Zambon A., Pauletto P. C-reactive protein and interleukin-6 in vascular disease: culprits or passive bystanders?. J. Hypertens. 2003, 21:1787-1803.
38. Re F., Strominger J.L. Toll-like receptor 2 (TLR2) and TLR4 differentially activate human dendritic cells. J. Biol. Chem. 2001, 276:37692-37699.
39. Rusconi F., Parizzi F., Garlaschi L., Assael B.M., Sironi M., Ghezzi P., Mantovani A. Interleukin 6 activity in infants and children with bacterial meningitis. The Collaborative Study on Meningitis. Pediatr. Infect. Dis. J. 1991, 10:117-121.
40. Samuvel D.J., Sundararaj K.P., Li Y., Lopes-Virella M.F., Huang Y. Adipocyte-mononuclear cell interaction. Toll-like receptor 4 activation, and high glucose synergistically up-regulate osteopontin expression via an interleukin 6-mediated mechanism. J. Biol. Chem. 2010, 285:3916-3927.
41. Strassburger M., Braun H., Reymann K.G. Anti-inflammatory treatment with the p38 mitogen-activated protein kinase inhibitor SB239063 is neuroprotective, decreases the number of activated microglia and facilitates neurogenesis in oxygen-glucose-deprived hippocampal slice cultures. Eur. J. Pharmacol. 2008, 592:55-61.
42. Sundararaj K.P., Samuvel D.J., Li Y., Nareika A., Slate E.H., Sanders J.J., Lopes-Virella M.F., Huang Y. Simvastatin suppresses LPS-induced MMP-1 expression in U937 mononuclear cells by inhibiting protein isoprenylation-mediated ERK activation. J. Leukoc. Biol. 2008, 84:1120-1129.
43. Sundararaj K.P., Samuvel D.J., Li Y., Sanders J.J., Lopes-Virella M.F., Huang Y. Interleukin-6 released from fibroblasts is essential for up-regulation of matrix metalloproteinase-1 expression by U937 macrophages in coculture: cross-talking between fibroblasts and U937 macrophages exposed to high glucose. J. Biol. Chem. 2009, 284:13714-13724.
44. Sundstrom C., Nilsson K. Establishment and characterization of a human histiocytic lymphoma cell line (U-937). Int. J. Cancer 1976, 17:565-577.
45. Thirunavukkarasu C., Watkins S.C., Gandhi C.R. Mechanisms of endotoxin-induced NO, IL-6, and TNF-alpha production in activated rat hepatic stellate cells: role of p38 MAPK. Hepatology 2006, 44:389-398.
46. Tobias P., Curtiss L.K. Thematic review series: the immune system and atherogenesis, paying the price for pathogen protection: toll receptors in atherogenesis. J. Lipid Res. 2005, 46:404-411.
47. Tsukumo D.M., Carvalho-Filho M.A., Carvalheira J.B., Prada P.O., Hirabara S.M., Schenka A.A., Araujo E.P., Vassallo J., Curi R., Velloso L.A., Saad M.J. Loss-of-function mutation in Toll-like receptor 4 prevents diet-induced obesity and insulin resistance. Diabetes 2007, 56:1986-1998.
48. Vanden Berghe W., De Bosscher K., Boone E., Plaisance S., Haegeman G. The nuclear factor-kappaB engages CBP/p300 and histone acetyltransferase activity for transcriptional activation of the interleukin-6 gene promoter. J. Biol. Chem. 1999, 274:32091-32098.
49. Vanden Berghe W., Plaisance S., Boone E., De Bosscher K., Schmitz M.L., Fiers W., Haegeman G. p38 and extracellular signal-regulated kinase mitogen-activated protein kinase pathways are required for nuclear factor-kappaB p65 transactivation mediated by tumor necrosis factor. J. Biol. Chem. 1998, 273:3285-3290.
50. Williams J.A., Pontzer C.H., Shacter E. Regulation of macrophage interleukin-6 (IL-6) and IL-10 expression by prostaglandin E2: the role of p38 mitogen-activated protein kinase. J. Interferon Cytokine Res. 2000, 20:291-298.
51. Yamato K., el-Hajjaoui Z., Simon K., Koeffler H.P. Modulation of interleukin-1 beta RNA in monocytic cells infected with human immunodeficiency virus-1. J. Clin. Invest. 1990, 86:1109-1114.
52. Zampetaki A., Zhang Z., Hu Y., Xu Q. Biomechanical stress induces IL-6 expression in smooth muscle cells via Ras/Rac1-p38 MAPK-NF-kappaB signaling pathways. Am. J. Physiol. Heart Circ. Physiol. 2005, 288:H2946-H2954.